Protection of BNT162b2 Vaccine Booster Against Covid-19 in Israel (NEJM) At least 12 days after the booster dose, the rate of confirmed infection was lower in the booster group than in the nonbooster group by a factor of 11.3 (95% confidence interval [CI], 10.4 to 12.3); the rate of severe illness was lower by a factor of 19.5 (95% CI, 12.9 to 29.5). In a secondary analysis, the rate of confirmed infection at least 12 days after vaccination was lower than the rate after 4 to 6 days by a factor of 5.4 (95% CI, 4.8 to 6.1).
(J. Harris: This is one of a series of reports from Israel regarding a 3rd. v
Pfizer vaccination shot. If you are >65 or are fragile, take a third shot. I did.)
CONGRATULATION MISD STAFF AND SCHOOL BOARD AND STUDENTS:
MISD SCHOOLS CONTINUE TO CONTROL COVID CASES
STATE CASES ARE ALSO DIMINISHING
1. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Through 6 Months (NEJM) BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy.
2. Parenting a Child Under 12 in the Age of Delta: ‘It’s Like a Fire Alarm Every Day’ (Washington Post) With a vaccine for children ages 5 to 11 unlikely to be approved for at least a few more months, parents of young children are weighing a dizzying array of variables every day as they try to navigate the risks of covid against the mental health and physical consequences of social isolation and their own livelihood.
FROM NEJM A HISTORICAL LOOK AT MASKS
EAST TEXAS AREA COMPARISONS (NYT):
AND LAST BUT NOT LEASED: